Highlights and Quick Summary
- Research and Development (R&D) Expenses Growth for the quarter ending March 31, 2022 was -29.25% (a -22.27% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development (R&D) Expenses Growth increased by 58.19%
- Annual Research and Development (R&D) Expenses Growth for 2021 was -24.28% (a -1377.89% decrease from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2020 was 1.9% (a -92.44% decrease from previous year)
- Annual Research and Development (R&D) Expenses Growth for 2019 was 25.12% (a -395.18% decrease from previous year)
- Twelve month Research and Development (R&D) Expenses Growth ending March 31, 2022 was -31.23% (a 28.62% increase compared to previous quarter)
- Twelve month trailing Research and Development (R&D) Expenses Growth increased by 491.48% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| -31.23% | -24.28% | -17.91% | -5.28% |
Visit stockrow.com/NVCN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development (R&D) Expenses Growth of Neovasc Inc.
Most recent Research and Development (R&D) Expenses Growthof NVCN including historical data for past 10 years.Interactive Chart of Research and Development (R&D) Expenses Growth of Neovasc Inc.
Neovasc Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | -29.25% | – | – | – | – |
| 2021 | -37.63% | -36.8% | -18.49% | 2.17% | -24.28% |
| 2020 | -15.61% | 15.19% | 10.64% | 6.68% | 1.9% |
| 2019 | 47.33% | 36.86% | 7.51% | 6.02% | 25.12% |
| 2018 | 23.68% | -21.07% | -9.23% | -20.86% | -8.51% |
| 2017 | -22.17% | -6.75% | -25.49% | 23.78% | -9.68% |
| 2016 | 6.24% | -3.41% | 33.29% | 18.98% | 12.71% |
| 2015 | 0.89% | 53.44% | 50.19% | 209.14% | 47.97% |
| 2014 | 96.09% | 77.78% | 81.53% | 13.27% | 74.61% |
| 2013 | 119.05% | 89.47% | 36.52% | 18.07% | 67.09% |
| 2012 | -54.35% | -47.22% | -26.75% | -15.31% | 51.91% |
| 2011 | – | – | – | – | -34.17% |
Business Profile of Neovasc Inc.
Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.